In this review:
- OS analysis from the ADAURA trial of adjuvant osimertinib
- TTFields therapy + SOC in metastatic NSCLC following platinum failure
- Sotorasib + carboplatin-pemetrexed in advanced non-squamous NSCLC with KRAS G12C mutation
- JDQ443 in KRAS G12C-mutated solid tumours including NSCLC
- Encorafenib + binimetinib in BRAF V600E-mutated metastatic NSCLC
- Adjuvant atezolizumab vs best supportive care by KRAS status in stage II-IIIA NSCLC
- APG-2449 has potential as a treatment for drug-resistant NSCLC
- Preliminary results from the Female Asian Nonsmoker Screening Study
- Cisplatin/pemetrexed ± pembrolizumab for malignant pleural mesothelioma
- Biomarker subgroup analysis of CodeBreaK 200 trial
- Pembrolizumab + platinum-based chemotherapy followed by resection then pembrolizumab for early-stage NSCLC
Please login below to download this issue (PDF)